Eads & Heald Investment Counsel decreased its position in Idexx Laboratories Inc. (NASDAQ:IDXX) by 9.3% during the second quarter, Holdings Channel reports. The institutional investor owned 7,581 shares of the company’s stock after selling 773 shares during the period. Eads & Heald Investment Counsel’s holdings in Idexx Laboratories were worth $704,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of IDXX. State Street Corp raised its stake in Idexx Laboratories by 0.5% in the first quarter. State Street Corp now owns 2,348,640 shares of the company’s stock worth $183,953,000 after buying an additional 11,533 shares in the last quarter. Geode Capital Management LLC raised its stake in Idexx Laboratories by 4.0% in the first quarter. Geode Capital Management LLC now owns 576,331 shares of the company’s stock worth $45,138,000 after buying an additional 22,351 shares in the last quarter. Renaissance Technologies LLC raised its stake in Idexx Laboratories by 242.6% in the first quarter. Renaissance Technologies LLC now owns 437,504 shares of the company’s stock worth $34,265,000 after buying an additional 309,804 shares in the last quarter. Franklin Resources Inc. raised its stake in Idexx Laboratories by 36.9% in the first quarter. Franklin Resources Inc. now owns 410,613 shares of the company’s stock worth $32,159,000 after buying an additional 110,604 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Idexx Laboratories by 43.2% in the first quarter. Goldman Sachs Group Inc. now owns 391,756 shares of the company’s stock worth $30,683,000 after buying an additional 118,115 shares in the last quarter. 91.58% of the stock is currently owned by institutional investors and hedge funds.
Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) traded up 0.42% during trading on Friday, hitting $111.20. The company’s stock had a trading volume of 105,961 shares. The company has a market cap of $9.96 billion, a PE ratio of 50.41 and a beta of 0.41. The firm’s 50 day moving average price is $112.18 and its 200-day moving average price is $96.25. Idexx Laboratories Inc. has a 52 week low of $63.48 and a 52 week high of $117.84.
Idexx Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 2nd. The company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.12. The business had revenue of $467 million for the quarter, compared to analyst estimates of $444.83 million. Idexx Laboratories had a net margin of 11.94% and a negative return on equity of 414.67%. The business’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 EPS. On average, analysts predict that Idexx Laboratories Inc. will post $2.36 earnings per share for the current year.
Several equities analysts recently commented on IDXX shares. Zacks Investment Research raised Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 target price on the stock in a report on Thursday, August 4th. Canaccord Genuity increased their target price on Idexx Laboratories from $90.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 20th. Bank of America Corp. reissued a “neutral” rating on shares of Idexx Laboratories in a report on Thursday, September 29th. Stifel Nicolaus increased their target price on Idexx Laboratories from $120.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. Finally, Northcoast Research raised Idexx Laboratories from a “sell” rating to a “neutral” rating in a report on Wednesday, August 3rd. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $105.20.
In related news, Director William T. End sold 5,000 shares of Idexx Laboratories stock in a transaction on Friday, August 5th. The shares were sold at an average price of $108.50, for a total transaction of $542,500.00. Following the transaction, the director now owns 53,564 shares in the company, valued at approximately $5,811,694. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barry C. Johnson sold 9,924 shares of Idexx Laboratories stock in a transaction on Monday, August 15th. The shares were sold at an average price of $111.37, for a total transaction of $1,105,235.88. Following the transaction, the director now owns 13,484 shares in the company, valued at approximately $1,501,713.08. The disclosure for this sale can be found here. Corporate insiders own 2.79% of the company’s stock.
Idexx Laboratories Company Profile
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories Inc. (NASDAQ:IDXX).
Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.